Platelet-Rich and Concentrated Platelet-Poor Plasma to Reduce Air Leak Post-Lobectomy: A Randomized Controlled Trial
This study has been completed.
Sponsor:
Biomet Biologics, LLC
Collaborator:
University of Western Ontario, Canada
Information provided by (Responsible Party):
Biomet, Inc. ( Biomet Biologics, LLC )
ClinicalTrials.gov Identifier:
NCT00665912
First received: April 21, 2008
Last updated: December 5, 2011
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether the use of platelet-rich plasma (PRP) and concentrated platelet-poor plasma (PPPc) can reduce the duration of post-operative air leak after lobectomy for lung tumours.
| Condition | Intervention |
|---|---|
|
Lung Cancer |
Procedure: Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively Procedure: Standard post-lobectomy wound care |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Platelet-Rich and Concentrated Platelet Poor Plasma to Reduce Air Leak Post Lobectomy: A Randomized Controlled Trial |
Resource links provided by NLM:
Further study details as provided by Biomet, Inc.:
Primary Outcome Measures:
- Duration of postoperative air leak [ Time Frame: Every 4 hours of postop hospital stay, between 4-6 weeks postop ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Incidence of air leak, Prolonged air leak (> days), Complications [ Time Frame: Every 4 hours of postop hospital stay, between 4-6 weeks postop ] [ Designated as safety issue: No ]
| Enrollment: | 204 |
| Study Start Date: | January 2008 |
| Study Completion Date: | November 2010 |
| Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1
Standard post-lobectomy wound care plus use of PRP and PPPc in the thoracic cavity.
|
Procedure: Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively
GPS is used to create the platelet rich plasma (PRP). Plasmax is used to create the concentrated platelet-poor plasma (PPPc). Both PRP and PPPc will be used for wound care in the thoracic cavity post-lobectomy.
|
|
Active Comparator: 2
Standard post-lobectomy wound care in the thoracic cavity
|
Procedure: Standard post-lobectomy wound care
Standard post-lobectomy wound care
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients requiring a lobectomy
Exclusion Criteria:
- Pneumonectomy
- Sleeve lobectomy
- Determination of unresectability (prior to the initiation of lobectomy)
- Wedge resection alone
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00665912
Locations
| Canada, Ontario | |
| University of Western Ontario: Division of Thoracic Surgery | |
| London, Ontario, Canada, N6A 5W9 | |
Sponsors and Collaborators
Biomet Biologics, LLC
University of Western Ontario, Canada
Investigators
| Principal Investigator: | Richard Inculet, MD, FRCSC, FACS | University of Western Ontario, Canada |
| Study Chair: | Darrin Payne, MD | University of Western Ontario, Canada |
| Study Chair: | Dalilah Fortin, MD | University of Western Ontario, Canada |
| Study Chair: | Richard Malthaner, MD | University of Western Ontario, Canada |
| Study Chair: | Robert Humphrey, MD | University of Western Ontario, Canada |
More Information
No publications provided
| Responsible Party: | Biomet, Inc. ( Biomet Biologics, LLC ) |
| ClinicalTrials.gov Identifier: | NCT00665912 History of Changes |
| Other Study ID Numbers: | BBI-004 |
| Study First Received: | April 21, 2008 |
| Last Updated: | December 5, 2011 |
| Health Authority: | Canada: Ethics Review Committee |
Additional relevant MeSH terms:
|
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 21, 2013